{"id":"NCT00549549","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Celebrex In Acute Gouty Arthritis Study","officialTitle":"A Phase 3, Randomized, Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Efficacy And Safety Of Celecoxib (CelebrexÂ®) And Indomethacin In The Treatment Of Moderate To Severe Acute Gouty Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2009-12","completion":"2009-12","firstPosted":"2007-10-26","resultsPosted":"2011-02-24","lastUpdate":"2021-02-21"},"enrollment":402,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Gouty"],"interventions":[{"type":"DRUG","name":"Indomethacin","otherNames":[]},{"type":"DRUG","name":"Celecoxib","otherNames":[]},{"type":"DRUG","name":"Celecoxib","otherNames":[]},{"type":"DRUG","name":"Celecoxib","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"},{"label":"4","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation of gouty arthritis.","primaryOutcome":{"measure":"Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity","timeFrame":"Baseline and Day 2","effectByArm":[{"arm":"Celecoxib 50 mg","deltaMin":3.03,"sd":0.67},{"arm":"Celecoxib 400/200 mg","deltaMin":2.73,"sd":0.62},{"arm":"Celecoxib 800/400 mg","deltaMin":2.84,"sd":0.69},{"arm":"Indomethacin 50 mg","deltaMin":2.83,"sd":0.76}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":81,"countries":["United States","Canada","Colombia","Costa Rica","Mexico","Peru","Philippines","Russia","South Korea","Spain","Taiwan","Thailand"]},"refs":{"pmids":["21849262"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3191219&StudyName=Celebrex%20In%20Acute%20Gouty%20Arthritis%20Study"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":101},"commonTop":["Gouty arthritis","Headache","Gout","Diarrhoea","Dizziness"]}}